Key result
MTHFR rs3737964 AG genotype linked to ~46% lower risk of capecitabine-induced hand-foot syndrome.
Why the study?
Hand-foot syndrome is a common adverse effect of capecitabine, prompting investigation of whether single nucleotide polymorphisms in capecitabine metabolism genes can serve as predictive biomarkers in patients with metastatic breast cancer.
Do polymorphisms in MTHFR and TYMS predict capecitabine-induced hand-foot syndrome in patients with metastatic breast cancer?
Observational (n=342)
Do polymorphisms in MTHFR and TYMS predict capecitabine-induced hand-foot syndrome in patients with metastatic breast cancer?
Odds Ratio: 0.54 (95% CI 0.31–0.97)
p-value: p=0.038
Polymorphisms in TYMS and MTHFR genes can serve as pharmacogenetic markers to predict the risk of capecitabine-induced hand-foot syndrome in patients with metastatic breast cancer.
May aid risk stratification for capecitabine hand-foot syndrome; hypothesis-generating and requires prospective validation before clinical use.
Background Breast cancer is a global problem, and a large number of new cases are diagnosed every year. Capecitabine is effective in patients with metastatic breast cancer (MBC). Hand‐foot syndrome (HFS) is a common adverse effect of capecitabine. In this study, we investigated the association between single nucleotide polymorphisms (SNPs) in genes involved in capecitabine metabolism pathways and capecitabine‐induced HFS in Chinese patients with MBC to identify some predictive genetic biomarkers. Methods We selected 3 genes involved in capecitabine metabolism and screened genetic variants in these target genes. We genotyped a total of 22 SNPs in the thymidylate synthase gene ( TYMS ), the methylene tetrahydrofolate reductase gene ( MTHFR ), and the ribonucleotide reductase M1 gene ( RRM1 ) in 342 MBC patients treated with capecitabine‐based chemotherapy. The genotype distributions of each SNP in patients with and without HFS were assessed using Pearson's χ 2 test, and the relationship between HFS and genotypes of SNPs was determined using logistic regression analysis. The association between SNPs and their corresponding gene expression was analyzed using the Blood expression quantitative trait loci (eQTL) browser online tools. Results We found 4 positive sites for HFS in the TYMS and MTHFR genes: TYMS rs2606241 ( P = 0.022), TYMS rs2853741 ( P = 0.019), MTHFR rs3737964 ( P = 0.029), and MTHFR rs4846048 ( P = 0.030). Logistic regression analyses showed that the genotype AG of MTHFR rs3737964 [odds ratio (OR) = 0.54, 95% confidence interval (CI) 0.31–0.97, P = 0.038] and MTHFR rs4846048 (OR = 0.54, 95% CI 0.30–0.98, P = 0.042) were protective factors of HFS, whereas the genotype CT of TYMS rs2853741 (OR = 2.25, 95% CI 1.31–3.87, P = 0.012) increased the risk of HFS. The association between the genotype GT of TYMS rs2606241 (OR = 1.27, 95% CI 0.73–2.23, P = 0.012) and HFS was uncertain. Further eQTL analyses confirmed that the alleles of rs3737964 and rs4846048 affected the gene expression levels of MTHFR in cis . Conclusions We have identified four potentially useful pharmacogenetic markers, TYMS rs2606241, TYMS rs2853741, MTHFR rs3737964, and MTHFR rs4846048 to predict capecitabine‐induced HFS in MBC patients.
No takes yet. Share an insight, caveat, or question.
Lin et al. (2019) conducted an observational in Metastatic breast cancer (n=342). MTHFR and TYMS gene polymorphisms vs. Alternative genotypes was evaluated on Capecitabine-induced hand-foot syndrome (HFS) (OR 0.54, 95% CI 0.31-0.97, p=0.038). The MTHFR rs3737964 AG genotype was associated with a reduced risk of capecitabine-induced hand-foot syndrome (OR 0.54; 95% CI 0.31-0.97; P=0.038), while TYMS rs2853741 CT increased the risk.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: